“The drug maker Novartis concealed manipulated data from the Food and Drug Administration while applying for approval of an extremely expensive gene therapy treatment and then delayed reporting the issue, the agency said on Tuesday….(T)he F.D.A. would continue to investigate and would determine whether Novartis should face civil or criminal penalties.New York Times
Shares of Novartis, a Swiss drugmaker that also makes the multiple sclerosis drug Gilenya, were down 2.77 percent, at $88.22 a share, on Tuesday.”
August 6, 2019
“The public ‘expects us to have accurate data when we approve products’”
Click on Read More (below) for full text (no paywall).
Reputation risk: peril of stakeholders’ disappointment and anger.
Risk governance and management, risk financing in insurance captives, and risk transfer through reputation insurances comprise the constituent elements of a comprehensive enterprise reputation risk solution.
What’s your strategy?